



## Dimerix Ltd Company Profile

### Overview

Dimerix Limited (ASX: DXB) is a clinical-stage drug development company discovering and developing new therapeutic treatments identified using its proprietary drug discovery platform.

Our lead program, DMX-200, is currently in Phase 2 clinical trials for Chronic Kidney Disease (CKD). We have secured US Orphan Drug Designation for Focal Segmental Glomerulosclerosis (FSGS) for this program. Dimerix is guided by an experienced board and management with track records of delivering significant long-term shareholder value and returns.

### Speaker Profile

#### Kathy Harrison, Chief Executive Officer, Dimerix Ltd



Kathy has around 25 years' experience within the Australian Biotech Industry, having performed various drug development and strategic roles in 3 ASX listed Biotech companies prior to Dimerix, and spending 9 years in private practice as a patent attorney.

Kathy's approach to creating shareholder value is focused on leveraging leading science, through innovative commercial and IP strategy, and diligent drug development processes.

Kathy holds a Master of Science from Manchester University (UK), is a Registered Patent and Trade Mark Attorney in Australia and Fellow of the Institute of Patent and Trade Mark Attorneys.

For more information, please visit: [dimerix.com](http://dimerix.com)